Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive intermittent docetaxel for metastatic castration-resistant prostate cancer
ACTRN12621000747820Phase 2Not yet recruiting
- Sponsor
- Calvary Mater Newcastle
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in castration-resistant prostate cancer (CRPC), sponsored by Calvary Mater Newcastle. Primary endpoints: Tolerability of adaptively dosed docetaxel and Acceptability of adaptively dosed docetaxel. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
docetaxel
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ACTRN12621000747820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000747820.